Auris Medical Holding AG, Zug, Switzerland and Otonomy Inc., San Diego, Calif., are set to release late-stage data from drug trials on treatments that could be used for tinnitus and Ménière’s disease, according to an article in Reuters.
Otonomy is expected to release their data from the Ménière’s trial in the second half of 2017; analysts predict the drug could generate peak sales of $603 million, according to the article. Auris’ data is expected in 2018 and could generate peak sales of $250 million, according to Reuters.
To read the full article, please visit the Reuters website here.
Hearing Review has reported on Auris Medical Holding’s peer-reviewed research on AM-101 as well as the 2016 results of Otonomy’s clinical trials of OTO-104 to treat Ménière’s disease; there are currently no FDA-approved drugs to treat Ménière’s disease.
Source: Reuters, Hearing Review
